Key result
[68Ga]Ga-Pentixafor PET integrated with contrast-enhanced CT effectively localizes adrenal nodules in primary aldosteronism.
Why the study?
Does [68Ga]Ga-Pentixafor PET integrated with contrast-enhanced CT improve visualization and localization of adrenal nodules in patients with clinically suspected primary aldosteronism?
Observational (n=35)
Does [68Ga]Ga-Pentixafor PET integrated with contrast-enhanced CT improve visualization and localization of adrenal nodules in patients with clinically suspected primary aldosteronism?
[68Ga]Ga-Pentixafor PET integrated with contrast-enhanced CT is capable of identifying and localizing various adrenal lesions in patients with suspected primary aldosteronism.
May enhance noninvasive localization in primary aldosteronism; extends hybrid PET/CT options but leaves open outcome validation.
RESULTS: Among these 35 patients, a total of 56 adrenal lesions including APA (n = 26), idiopathic hyperplasia (IHA, n = 26), nonfunctioning adenomas (NFA, n = 3), and familial hyperaldosteronism (n = 1) were identified and segmented from both [ CONCLUSION: The integration of [
No takes yet. Share an insight, caveat, or question.
Feng et al. (2026) conducted an observational in Primary aldosteronism (n=35). [68Ga]Ga-Pentixafor PET integrated with contrast-enhanced CT was evaluated on Identification of adrenal lesions. [68Ga]Ga-Pentixafor PET integrated with contrast-enhanced CT identified 56 adrenal lesions, including 26 APA and 26 IHA, in 35 patients with clinically suspected primary aldosteronism.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: